Seres Therapeutics Inc. Common Stock (MCRB)

FairStock Score: 50/100 — MIXED

Key Financials

Strengths

• Solid return on equity of 19.6% above cost of capital

Concerns

• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
• Weak Piotroski F-Score of 2/9 suggests deteriorating financial quality across multiple dimensions
• Altman Z-Score of -9.6 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Seres Therapeutics Inc. Common Stock is a micro-cap healthcare company valued at $78 million. Revenue stands at $789,000, though the company is currently unprofitable. From a quality standpoint, Seres shows weak Piotroski F-Score of 2/9 signaling deteriorating fundamentals and distressed Altman Z-Score of -9.6 warrants caution. On valuation, the stock is attractively valued at 12.6x earnings, with a modest 1% margin of safety vs Graham Number. Growth dynamics show profit growth of 1.9%. Our composite FairStock Score of 50/100 reflects mixed fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.

Bull Case

The market underappreciates Seres's consistent 20% ROE at just 13x earnings—a re-rating toward sector peers could unlock 30-50% upside. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer